Treats metastatic carcinoid tumors. ANDA 77457, held by Fresenius Kabi USA. Octreotide Acetate.
As of Nov 16, 2026, ANDA 77457 (Octreotide Acetate (Preservative Free)), held by Fresenius Kabi USA, was first approved by FDA on Feb 10, 2006, with 9 approved supplements and 0 published complete response letters.
Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly: To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. Carcinoid Tumors: For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. Vasoactive Intestinal Peptide Tumors (VIPomas): For the treatment of profuse watery diarrhea associated with VIP-secreting tumors.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 10, 2006 | Original application | Approved | None posted |
| Octreotide Acetate (Preservative Free)EQ 0.05MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide Acetate (Preservative Free)EQ 0.1MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide Acetate (Preservative Free)EQ 0.5MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Sep 25, 2024 | Supplement 21Labeling · Standard review | Approved | None posted |
| Sep 25, 2024 | Supplement 24Labeling · Standard review | Approved | None posted |
| Jun 30, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jun 30, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jun 30, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jun 30, 2023 | Supplement 19Labeling · Standard review | Approved | None posted |
| Mar 9, 2018 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 9, 2018 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 30, 2012 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 10, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters